Chartwell Investment Partners’s Trillium Therapeutics Inc. TRIL Stock Holding History

Chartwell Investment Partners’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-98,177	Closed	-$1.72M	–	457
2021 Q3	$1.72M	Hold	98,177	–	–	0.05%	316
2021 Q2	$952K	Buy	98,177 +881	+0.9%	+$8.29K	0.03%	380
2021 Q1	$1.04M	Sell	97,296 -5,228	-5%	-$64.7K	0.03%	358
2020 Q4	$1.51M	Sell	102,524 -23,561	-19%	-$340K	0.05%	318
2020 Q3	$1.79M	Buy	126,085 +25,093	+25%	+$250K	0.07%	288
2020 Q2	$817K	Buy	+100,992	New	+$625K	0.03%	349

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Chartwell Investment Partners's TRIL Position: Q4 2021 in Review

Chartwell Investment Partners sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 98,177 shares — an estimated $1.72M sold.

Chartwell Investment Partners first reported a position in TRIL in Q2 2020 and held it in 6 quarters. The position peaked at $1.79M in Q3 2020. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Chartwell Investment Partners reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Chartwell Investment Partners sold 98,177 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $1.72M.
Chartwell Investment Partners first reported a position in Trillium Therapeutics Inc. in Q2 2020 and held it in 6 quarters.
Chartwell Investment Partners's Trillium Therapeutics Inc. position peaked at $1.79M in Q3 2020.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Chartwell Investment Partners's 13F filing for Q4 2021, filed 15 Feb 2022.